Preclinical validation of 111In-girentuximab-F(ab′)2 as a tracer to image hypoxia related marker CAIX expression in head and neck cancer xenografts

Hypoxia is a major cause of radio- and chemoresistance. Carbonic anhydrase IX (CAIX) is an endogenous hypoxia-related marker and an important prognostic marker. Assessment of CAIX expression may allow patient selection for hypoxia or CAIX-targeted treatment. The radioactive tracer 111In-girentuximab-F(ab′)2 targets CAIX and can be used for SPECT imaging. Aim of this study was to validate and optimize 111In-girentuximab-F(ab′)2 for imaging of CAIX expression in head and neck tumor xenografts.

http://ift.tt/2wvK8da